Mr. Yi-Kuei Chen serves as Chief Operating Officer and Director of Apollomics. He brings to the Company over two decades of leadership experience across biotechnology, venture capital, and asset management, with a strong track record in private equity investments and corporate governance.

Mr. Chen is a co-founder of Maxpro Ventures, where his expertise in asset management has led to the successful execution of more than 60 private equity investment transactions across the United States and the Asia-Pacific region. His past investments span a broad range of innovative biotechnology and pharmaceutical companies, including Acepodia, SyneuRx, GenScript, JHL Biotech, Foresee Pharmaceuticals, HEC Pharma, and ACT Genomics Holdings.

Prior to co-founding Maxpro Ventures, Mr. Chen was Senior Director at Integral Group, where he co-led the firm’s Asian transaction process, managed its Shanghai branch, and served on the boards of portfolio companies such as Generon Corporation, FusionVax, Inc., BioLite, Inc., and Flora International Group Co., Ltd. Earlier in his career, from 1999 to 2012, Mr. Chen held senior management positions in the investment division of Central Investment Holdings. During this period, he oversaw a series of successful investments, including Tanox and Biopure, and executed a landmark transaction in 2002 with the acquisition of SEEDNet by New Century InfoComm Tech. He also held board positions at Singfor Life Insurance Company, and CTCI Corporation.

Mr. Chen received an MBA from Syracuse University and an M.S. from the University of Minnesota.